{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52.7","upperLimit":"79.3","value":"66.0"},{"groupId":"OG001","lowerLimit":"64.1","upperLimit":"87.7","value":"75.9"},{"groupId":"OG002","lowerLimit":"57.1","upperLimit":"82.1","value":"69.9"},{"groupId":"OG003","lowerLimit":"70.8","upperLimit":"92.4","value":"81.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"56"}],"units":"Participants"}],"description":"The Kaplan-Meier method will be used to estimate 5-year OS, defined as the time from study enrollment to death from any cause, or to date of last contact. Estimates are reported with 95% confidence intervals. Data below represents all molecular subgroups combined.","dispersionType":"95% Confidence Interval","groups":[{"description":"Medulloblastoma patients who received regimen A (no carboplatin / no isotretinoin)","id":"OG000","title":"Regimen A (Medulloblastoma Patients)"},{"description":"Medulloblastoma patients who received regimen B (carboplatin / no isotretinoin)","id":"OG001","title":"Regimen B (Medulloblastoma Patients)"},{"description":"Medulloblastoma patients who received regimen C (no carboplatin / isotretinoin)","id":"OG002","title":"Regimen C (Medulloblastoma Patients)"},{"description":"Medulloblastoma patients who received regimen D (carboplatin / isotretinoin)","id":"OG003","title":"Regimen D (Medulloblastoma Patients)"}],"paramType":"NUMBER","populationDescription":"Eligible medulloblastoma patients are included.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Percent Probability of Overall Survival (OS) for Patients With Medulloblastoma","type":"SECONDARY","unitOfMeasure":"Percent Probability"}